Used in the treatment of Parkinson’s disease, particularly as an add-on therapy to levodopa in patients experiencing motor fluctuations. It helps prolong the duration of symptom control by inhibiting the breakdown of dopamine through selective and reversible inhibition of monoamine oxidase-B (MAO-B). Additionally, it modulates glutamate release, which may contribute to improved motor function and reduced off-time. Its dual mechanism supports smoother symptom management with a favorable safety profile, especially regarding dietary restrictions compared to non-selective MAO inhibitors.